BLR Bio

About BLR Bio

BLR Bio is a privately held biotechnology company focused on developing breakthrough therapies for fibro-inflammatory diseases. They are at the forefront of fibro-inflammatory therapy development, targeting the myofibroblast to address a wide range of fibrotic diseases and cancer, with a mission to restore equilibrium in affected areas of the body.

Products & Services

Fibrosis Therapies:Therapies designed to restore equilibrium in areas of the body affected by persistent inflammation and fibrosis.

Cancer Therapies:Therapies aimed at restoring antitumor immunity and suppressing cancer cell proliferation and spread.

Specialties

Fibro-Inflammatory Therapy Fibrotic Diseases Cancer Therapy Myofibroblast Targeting

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 780000 MR: - FA: $780,000 FAN: 780000	D: 2023-02-14 FD: 2023-02-14	1 investors

Grant Latest

2023-02-14

$780K

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andrew Leask

Professor

J

James Varani

Professor and CSO JV Biolabs

R

Richard Stratton

MD, PhD

F

Frederick Tam

Ken and Mary Minton Chair of Renal Medicine

R

Robert Lafyatis

Thomas Medsger endowed Professor of Medicine and Director, Scleroderma Center and NIAMS, Center for Research Translation into Scleroderma Pathogenesis, University of Pittsburgh, School of Medicine

G

Giulia Taraboletti

Head, Tumor Microenvironment Laboratory

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

BLR Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised